Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Holdings Trimmed by Franklin Resources Inc.

Franklin Resources Inc. cut its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 26.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 692,028 shares of the company’s stock after selling 244,933 shares during the quarter. Franklin Resources Inc. owned about 1.60% of Kyverna Therapeutics worth $2,588,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Kyverna Therapeutics by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,780 shares of the company’s stock worth $635,000 after acquiring an additional 3,145 shares in the last quarter. Corebridge Financial Inc. boosted its position in shares of Kyverna Therapeutics by 42.3% in the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after buying an additional 3,810 shares during the period. Rhumbline Advisers grew its holdings in shares of Kyverna Therapeutics by 31.1% during the fourth quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock valued at $97,000 after buying an additional 6,153 shares in the last quarter. FMR LLC purchased a new stake in Kyverna Therapeutics in the 3rd quarter worth about $33,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Kyverna Therapeutics during the 4th quarter worth about $34,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KYTX. Morgan Stanley reduced their price target on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, April 1st. HC Wainwright lowered their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Kyverna Therapeutics has an average rating of “Buy” and a consensus price target of $18.33.

Kyverna Therapeutics Trading Up 10.2 %

Shares of Kyverna Therapeutics stock opened at $2.06 on Friday. The stock has a market capitalization of $89.02 million, a price-to-earnings ratio of -0.59 and a beta of 2.57. The firm’s 50-day moving average price is $2.51 and its two-hundred day moving average price is $3.78. Kyverna Therapeutics, Inc. has a 1-year low of $1.79 and a 1-year high of $24.59.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.01). As a group, equities research analysts predict that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.